We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Amarin has been teasing big plans for Vascepa marketing when—and if—the med wins a new cardiovascular prevention approval this fall. And now we know just how big those plans are.